Followers | 144 |
Posts | 27603 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, May 10, 2005 10:52:12 AM
Tuesday May 10, 7:00 am ET
TEL AVIV, Israel--(BUSINESS WIRE)--May 10, 2005--Compugen Ltd. (Nasdaq:CGEN - News) announced today the appointment of Alex Kotzer as President and Chief Executive Officer, effective September 1, 2005, after his relocation to Israel. Kotzer, whose most recent position was Vice President at Serono of Geneva, Switzerland, will replace current President and Chief Executive Officer Mor Amitai, Ph.D., who announced last October that he intends to resign from these positions before year end 2005.
ADVERTISEMENT
"Alex brings many years of relevant experience combined with a proven track record in managing biotech research, product development, and manufacturing in his previous positions at Serono and InterPharm," stated Martin Gerstel, Chairman of Compugen. "His background makes him ideal to lead Compugen, as we continue to expand and deepen our predictive research capabilities, and to advance the development and commercialization of our discovery engines as well as our diagnostic and therapeutic product candidates."
Gerstel added, "We are highly appreciative of Mor's efforts and accomplishments over the past decade. Compugen today is a world leader in advancing life science through the integration of mathematics and computational technologies with biology, and has established a unique position in the predictive discovery of potential therapeutic proteins and diagnostic biomarkers. These accomplishments, which are now providing us with ever-increasing potential for important medical contributions and substantial commercial success, have been made under Mor's guidance and leadership."
Kotzer commented, "I feel very privileged to join Compugen in the capacity of President and CEO at this important point in its development. Compugen's unique predictive approach to drug discovery, stemming from the integration of advanced mathematics and computational technologies with biology, sets it apart in philosophy and capabilities from other drug discovery and development companies. I look forward to the challenge of leading Compugen's outstanding team and contributing to the Company's continuing growth and future success."
For the past twelve years, Kotzer has been employed by Serono, a global biotechnology leader, headquartered in Switzerland, and by its Israeli affiliate, InterPharm. Initially he was President and Chief Executive Officer of InterPharm, which was at that time a public company. In 1999, he was promoted to Vice President of the parent company and relocated to Switzerland with responsibility for neurology and immunology product and process development, and for generating and executing the franchise's strategy. More recently, he was responsible for worldwide manufacturing of the active ingredients for all recombinant biological drugs of Serono. Kotzer has a B.Sc. in Chemical Engineering from the Technion, Haifa, Israel.
About Compugen
Compugen is a drug and diagnostic discovery company incorporating ideas and methods from mathematics, computer science, and physics into biology, chemistry and medicine. The Company's powerful predictive models and discovery engines are both advancing the understanding of important biological phenomena and enabling the discovery of numerous potential therapeutic products and diagnostic markers. The Company has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the Company; additional discoveries have been out-licensed for development. Among Compugen's customers and partners are leading pharmaceutical and diagnostic companies, such as Abbott Laboratories, Diagnostic Products Corporation, Novartis, and Pfizer. Compugen has established a small-molecule drug discovery affiliate - Keddem Bioscience, and an agricultural biotechnology affiliate - Evogene. For additional information, please visit Compugen's corporate Website at www.cgen.com.
http://biz.yahoo.com/bw/050510/105474.html?.v=1
Midas
Recent CGEN News
- Compugen to Present at Upcoming Antibody Industrial Symposium • PR Newswire (US) • 06/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 11:00:12 AM
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig • PR Newswire (US) • 05/30/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2024 11:00:07 AM
- Compugen Reports First Quarter 2024 Results • PR Newswire (US) • 05/20/2024 11:00:00 AM
- U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip • IH Market News • 05/20/2024 10:59:35 AM
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 11:02:08 AM
- Compugen Appoints David Silberman as Chief Financial Officer • PR Newswire (US) • 05/15/2024 11:00:00 AM
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Compugen to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 04/03/2024 11:00:00 AM
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:06:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:00:24 PM
- Compugen Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (US) • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 • PR Newswire (US) • 02/26/2024 12:00:00 PM
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 12:00:08 PM
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer • PR Newswire (US) • 02/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:10:06 PM
- Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 01/08/2024 12:05:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM